Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement-Reference-Cited by-同舟云学术

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Published:2011-02-04 Issue:5 Volume:25 Page:749-760
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Dimopoulos M A, ,Palumbo A,Attal M,Beksaç M,Davies F E,Delforge M,Einsele H,Hajek R,Harousseau J-L,da Costa F Leal,Ludwig H,Mellqvist U-H,Morgan G J,San-Miguel J F,Zweegman S,Sonneveld P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu20113.pdf

Reference80 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152–1157.

3. Rajkumar SV . Treatment of myeloma: cure vs control. Mayo Clinic Proc 2008; 83: 1142–1145.

4. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155–167.

5. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials;Therapeutic Advances in Medical Oncology;2024-01

2. Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma;American Society of Clinical Oncology Educational Book;2023-05

3. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma;Cancers;2022-12-16

4. Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective;Cost Effectiveness and Resource Allocation;2022-12-12

5. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease;Expert Review of Proteomics;2022-06-03